T0	Outcomes 60 79	efficacy and safety
T1	Outcomes 293 312	safety and efficacy
T2	Outcomes 484 518	serotonin (5-HT) receptor activity
T3	Outcomes 541 563	serotonin transporter.
T4	Outcomes 778 854	the primary efficacy end point being change from baseline at week 8 in MADRS
T5	Outcomes 892 901	measures.
T6	Outcomes 902 916	Adverse events
T7	Outcomes 942 1137	study, suicidal ideation and behavior were assessed using the Columbia-Suicide Severity Rating Scale (C-SSRS), and sexual dysfunction was assessed using the Arizona Sexual Experience (ASEX) scale
T8	Outcomes 1311 1341	the primary efficacy end point
T9	Outcomes 1419 1422	mg.
T10	Outcomes 1423 1511	Nausea, headache, dry mouth, constipation, diarrhea, vomiting, dizziness, and flatulence
T11	Outcomes 1586 1607	due to adverse events
T12	Outcomes 1877 1951	the C-SSRS, laboratory values, electrocardiogram, or vital sign parameters